Patients with a primary invasive or in situ melanoma had a significantly increased relative risk for developing a subsequent invasive melanoma, according to recent study results.
MRV Research
Melanoma detection enhanced with blood biomarkers
THE need for invasive skin biopsies could be reduced extensively with Edith Cowan University researchers working on ways to detect melanoma in early stages, using a blood test in conjunction with visual scans.
Exelixis presents final Phase 1b data on investigational MEK-BRAF inhibitor combination therapy for metastatic melanoma
Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis’ collaborator and a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation. Antoni Ribas, M.D., Ph.D., a professor in the department of medicine at Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, presented the data during a plenary session today at the 10th European Association of Dermato-Oncology (EADO) Congress.
New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1